2ND GENERATION GRIFFITHSIN MUTANTS FOR IMPROVED STABILITY AND SOLUBILITY (15042)
- *Abstract
-
2ND GENERATION GRIFFITHSIN MUTANTS FOR IMPROVED STABILITY AND SOLUBILITY (15042)
Features and Benefits Summary
Potent anti-viral protein with activity against HIV and other viruses
Possesses microbicidal capabilities
Expressed in plants
Composition can provide anti-viral capabilities for a wide variety of hosts
*This Technology is available for licensing, further development, or industrial partnering*
Market Opportunities
Griffithsin is a potent anti-viral protein with activity against HIV and other viruses, including hepatitis, herpes, Japanese encephalitis virus, and SARS-CoV. Researchers in this group identified oxidation sensitivity of the 1st generation Griffithsin and suggested modification of methionine (M78). Researchers next designed an improved 2nd generation of mutants with an amino acid substitution at M78. This modification allows the prevention of protein oxidation and increases the useable shelf-life of Griffithsin. With the identification of this mutant polypeptide sequence, widespread application is possible, because delivery to oxidative biologic compartments can be achieved with no impact on the protein structure. The Griffithsin mutants are currently expressed and purified from transient plant expression systems using plant expression vectors. Griffithsin mutants maintain antiviral activity and can then be administered to the host, either prophylactically or therapeutically, in order to inhibit viral infection. Additionally, the composition can further comprise other active pharmaceutical agents, such as immunomodulators and antibiotics to target or expand antiviral activity.
Technology
The Griffithsin mutants discovered have numerous benefits, as they are able to inhibit a wide variety of viruses in different hosts. These 2nd generation mutants allowed for the development of an improved active pharmaceutical ingredient for microbicide and antiviral applications. The modifications allowed for a Griffithsin mutant that has reduced methionine oxidation, increased shelf-life, improved solubility, and improved bioavailability at different pH ranges. Griffithsin mutants maintain antiviral activity with improved biophysical characteristics and can be given to patients who are at risk for exposure to a virus or have been newly exposed to a virus. Additionally, the Griffithsin mutant can be a component of an antiviral agent that can be given to patients topically, orally, transdermally or through aerosol formulations. There is great need for the development of an anti-viral component that can be applied to a variety of viruses and benefit several hosts.
Technology Status
- IP Status: PCT/US16/017267; Publication number WO2016130628A1.
- Development Status: Preclinical and early stage clinical trials as an HIV prophylactic
- Fields of Use Available: All
Researchers:
Dr. Joshua L. Fuqua
Dr. Lindsay Kramer
Dr. Tinoush Moulaei
Dr. Barry R O'Keefe
Dr. Kenneth E. Palmer
Dr. Lisa C. Rohan
- Country/Region
- USA
